UNSPSC 85816128: Introduction of other antineoplastic into peripheral artery, percutaneous approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of other antineoplastic into peripheral artery, percutaneous approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E05305

UNSPSC 85816128 Introduction of other antineoplastic into peripheral artery, percutaneous approach is a Commodity code that describes a specific medical procedure, yet the recent state and local procurement activity mapped to this code shows little alignment with its nominal scope. The code sees minimal legitimate demand in state and local contracting; instead, the recent opportunities tagged to it span telehealth delivery, PACE operations, cancer screening, occupational health services, medical director contracts, wellness programs, and various clinical staffing and support services—none of which involve antineoplastic drug administration into peripheral arteries.

The mismatch between the code's clinical procedure definition and the actual work being solicited suggests either systematic miscoding in state and local procurement systems or incidental tagging that does not reflect the core activity being purchased. State and local bodies issuing under this code include health plans (Inland Empire Health Plan in California), state health authorities (Nevada Health Authority), counties (DeKalb County Georgia, San Mateo County, Brevard County, Cobb County, Forsyth County, Jackson County Missouri, Sedgwick County Kansas, Ventura County, Seminole County Florida), cities (Atlanta, Phoenix, Ocala Florida), and school districts (Parkway School District), alongside regional health systems and special districts. Geographic spread covers California, Colorado, Florida, Georgia, Illinois, Kansas, Missouri, Nebraska, Nevada, New Jersey, New Mexico, New York, Oregon, Tennessee, and Texas. The code shows no decision-relevant recent activity targeting the procurement of antineoplastic infusion services; pursue opportunities only if your firm operates in one of the clinical or administrative service categories identified in the underlying solicitations, and verify the actual scope before investing bid resources.